RxSight <RXST.O>: BofA Global Research cuts price objective to $5.50 from $6.50
RXST•Related News
U.S. Goldmining Completes 2026 Drill Program Targeting High-Priority Porphyry Centers At Its 100% Owned Whistler Gold-Copper Project, Alaska
USGO•
GSK Canada signs LOI with pCPA for Blenrep multiple myeloma coverage talks
GSK•
Microsoft: Oppenheimer Raises Target Price to $570 From $515
MSFT•
Citigroup's Long Position in Bilibili Increases to 6.46%, Says HKEX
BILI•
Radian Group Inc. <RDN.N>: BTIG assumes coverage with Buy rating; price target $48
RDN•